Latest Comments
Managed Entry Agreements: Sharing Risk in Greece
When a payer cannot be certain a medicine is worth its price, the answer is increasingly not “no” — it is a contract that shares[…]
Preparing for the EU HTA Regulation: A Practical Roadmap
The EU HTA Regulation is now live, and the Joint Clinical Assessment is reshaping how evidence is judged across Europe. The companies that prepare early[…]
Market Access for Biosimilars: Beyond the Price Tag
Biosimilars have saved European health systems tens of billions of euros — yet uptake remains uneven, and market access is about far more than offering[…]
Market Access for Rare Disease Therapies: Navigating Uncertainty
Rare disease therapies can transform lives — but getting them reimbursed is one of the hardest challenges in market access. Small populations, limited data and[…]
The EU Joint Clinical Assessment: What It Means for Your Product
From January 2025, the way new medicines are clinically assessed in Europe changed. The Joint Clinical Assessment (JCA) introduces a single, EU-wide evaluation of clinical[…]
From Approval to Access: How Reimbursement Really Works in Greece
A marketing authorization lets you sell a medicine. Reimbursement is what lets patients actually receive it. In Greece, the two are separate processes — and[…]